Eunice Jane Beachy, ARNP Nurse Practitioner - Adult Health Medicare: Accepting Medicare Assignments Practice Location: 19500 10th Ave Ne, Ste 100, Poulsboe, WA 98370 Phone: 253-598-7500 Fax: 253-598-7505 |
News Archive
Ipsen today announced positive initial results from the double-blind phase III study of Dysport (abobotulinumtoxinA) in Adult Upper Limb spasticity. Regarding the primary endpoints, treatment with Dysport showed statistically significant response versus placebo in the improvement of muscle tone, as measured by the Modified Ashworth Scale.
Their findings, which will be highlighted at the upcoming 2005 American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference in San Francisco, brings renewed hope to the 4.5 million Americans who have Alzheimer's disease.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.
The University of New Hampshire will receive $1.8 million from the National Institutes of Health that will further molecular research to better understand drug interactions at the cellular level and help lead to the development of new targeted drugs to treat wide-spread metabolic, growth, neurological and visual disorders including diabetes and cancer.
› Verified 3 days ago